MedTrace Logo

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects

NCT01531322 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2018-09-07

No results posted yet for this study

Summary

This study will assess the safety and tolerability of a single dose of 13-valent Pneumococcal Conjugate Vaccine for approximately 1 month after vaccination sequentially in healthy Chinese adults aged 18 through 55 years, followed by children aged 3 through 5 years, and then infants aged approximately 2 months.

Conditions

  • Pneumococcal Infection

Interventions

BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
42 Days
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01531322 on ClinicalTrials.gov